Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own ...

BACKGROUND: A 3-dimensional hyperboloid model has been proposed to characterize ventricular tachycardia (VT) circuitry. We ...

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company ...

As an adjunct to bypass surgery for ischemic cardiomyopathy, a cardiac shockwave therapy aimed at regenerating ischemic myocardium boosted left ventricular ejection fraction (LVEF) and physical ...

November 22, 2011 (Orlando, Florida) — Results from a small phase 1 study provide some reason for optimism in the treatment of ischemic cardiomyopathy with autologous cardiac stem cells (CSCs) [1]. An ...

Performing CABG on top of optimal medical therapy is a cost-effective treatment option for patients with ischemic cardiomyopathy and reduced LV function, an analysis based on STICH/STICHES data ...

Please provide your email address to receive an email when new articles are posted on . Catheter ablation improved outcomes vs. antiarrhythmic drugs in patients with VT and ischemic cardiomyopathy.

The patient presented to the emergency department suffering from increasing shortness of breath, which he said had been ongoing for 6 months, noting that the dyspnea initially occurred only with ...

A multi-institution research team led by Georgetown University Medical Center has developed and validated a model estimating ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In certain patients with an ICD for primary prevention, ...

The Defibrillators in Non-ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) trial was conducted to evaluate the prophylactic implantation of an ICD to prevent sudden death in patients with ...